Summary from GEO: "Acute myelogenous leukemia (AML) is a high-risk malignancy characterized by a diverse spectrum of somatic genetic alterations. The mechanisms by which these mutations contribute to leukemia development and how this informs the use of targeted therapies is critical to improving outcomes. Importantly, how to target loss-of-function mutations has been a critical challenge in precision...

Summary from the GEO: "Acute myelogenous leukemia (AML) is a high-risk malignancy characterized by a diverse spectrum of somatic genetic alterations. The mechanisms by which these mutations contribute to leukemia development and how this informs the use of targeted therapies is critical to improving outcomes. Importantly, how to target loss-of-function mutations has been a critical challenge in precision...

This Dataset is a SuperSeries composed of the following SubSeries: GSE140359 DOT1L inhibitors block abnormal self-renewal induced by cohesin loss [RNA-seq] GSE140360 DOT1L inhibitors block abnormal self-renewal induced by cohesin loss [ChIP-seq] Data stored in this GEO relates to Acute myeloid leukemia (AML) and DOT1L inhibitors stored in two sequence formats.

From the dbGaP study description: "The genomic evolution of breast cancers exposed to systemic therapy and its effects on clinical outcome have not been broadly characterized. We integrated the genomic sequencing of 1918 breast cancers, including 1501 hormone receptor-positive tumors, with detailed clinical information and treatment outcomes. Functional mutations in ERBB2 and loss-of-function mutations...